HeartFlow, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $9.2M | 603 | 68.1% |
| Consulting Fee | $1.9M | 647 | 13.7% |
| Food and Beverage | $1.2M | 21,859 | 8.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $787,647 | 465 | 5.8% |
| Travel and Lodging | $296,831 | 1,080 | 2.2% |
| Education | $148,750 | 24 | 1.1% |
| Space rental or facility fees (teaching hospital only) | $21,000 | 10 | 0.2% |
| Grant | $13,000 | 4 | 0.1% |
| Entertainment | $654.34 | 7 | 0.0% |
| Honoraria | $249.80 | 4 | 0.0% |
| Gift | $83.55 | 1 | 0.0% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| Assessing Diagnostic Value of Non-invasive FFRCT in Coronary Care | $3.2M | 0 | 133 |
| 100 Analysis : 200 FFRct Analysis : 400 Clinical Studies : 424 PRECISE | $2.0M | 0 | 187 |
| 100 Analysis : 200 FFRct Analysis : 400 Clinical Studies : 438 JACS | $890,682 | 0 | 29 |
| Prospective Randomized Trial of Optimal Evaluation of Suspected Coronary Artery Disease | $654,643 | 0 | 5 |
| RetrospectivE study of FFRCT compared to mFFR and CTA In the post-market ENvironmEnt | $356,268 | 0 | 8 |
| Precise Study | $267,144 | 0 | 32 |
| Evaluation of FFRCT to improve efficacy and efficiency of management of Patients With Acute Chest Pain as compared to anatomic CCTA and Standard of Care | $245,460 | 0 | 3 |
| 100 Analysis : 200 FFRct Analysis : 400 Clinical Studies : 447 REVEALPLAQUE | $184,335 | 0 | 21 |
| REFINE Cardiovascular Imaging Core Lab. | $183,688 | 0 | 1 |
| 100 Analysis : 200 FFRct Analysis : 400 Clinical Studies : 448 MGH Type 2 MI | $168,551 | 0 | 6 |
| PRECISE, C6000136 Protocol #CP-907-001-A PI: Victor Marinnescu, MD | $160,300 | 0 | 7 |
| AI DErived Plaque Quantification: CCTA and AI-QCPA for Determining Effective CAD Management (DECIDE) | $114,550 | 0 | 17 |
| PRECISE, C6000148 Protocol #CP-907-001-A PI: Sorin Danciu, MD, | $102,250 | 0 | 1 |
| Prospective Randomized Trial of the Optimal Evaluation of Cardiac Symptoms and Revascularization (PRECISE) | $95,895 | 0 | 21 |
| Promise - CT - FFR Cost Effectiveness Analysis | $89,560 | 0 | 1 |
| SPECT vs CT vs. FFRCT: Diagnostic accuracy (using FFRCT as gold standard) | $78,576 | 0 | 4 |
| 100 Analysis : 200 FFRct Analysis : 400 Clinical Studies : 437 P3 | $69,500 | 0 | 1 |
| 100 Analysis : 200 FFRct Analysis : 400 Clinical Studies : 442 FFRct ACP | $64,800 | 0 | 2 |
| 100 Analysis : 200 FFRct Analysis : 400 Clinical Studies : 443 ADVANCE-ED | $52,640 | 0 | 8 |
| "The AFFECTS Study: Assessment of Fractional Flow reservE Computed Tomography versus Single photon emission computed tomography in the diagnosis of hemodynamically significant coronary artery disease " | $46,464 | 0 | 5 |
| The AFFECTS Study: Assessment of Fractional Flow reservE Computed Tomography versus | $42,079 | 0 | 5 |
| 100 Analysis : 200 FFRct Analysis : 201 FFRct (Default) | $30,150 | 0 | 2 |
| PRECISE, C6000136 Protocol #CP-907-001-A PI: Victor Marinescu, MD, | $29,550 | 0 | 3 |
| Assessing Diagnostic Value of Non-invasive FFRCT in Coronary CarE | $12,848 | 0 | 3 |
| PRECISE CP-907-001-A - IRB FEE | $12,500 | 0 | 1 |
| Prospective Randomized Trial of the Optimal Evaluation of Cardiac Symptoms and Revascularizaton -Protocol CP-907-001-A | $12,094 | 0 | 3 |
| PRECISE Protocol #CP-907-001-A | $11,000 | 0 | 1 |
| Precise Study -CP-907-001-A | $7,813 | 0 | 2 |
| CP-907-001-A PRECISE | $7,700 | 0 | 1 |
| PRECISE CP-907-001-A | $6,350 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Dr. Gregg Stone, M.d, M.D | Cardiovascular Disease | New York, NY | $453,542 | $0 |
| Dr. Mark Rabbat, Md, MD | Internal Medicine | Maywood, IL | $226,307 | $0 |
| Jamaluddin Moloo, Md, MD | Cardiovascular Disease | Aurora, CO | $183,751 | $0 |
| Sarah Rinehart, Md, MD | Cardiovascular Disease | Charleston, WV | $177,484 | $0 |
| Michael Gallagher, Md, MD | Cardiovascular Disease | Troy, MI | $176,448 | $0 |
| Dr. Geoffrey Rubin, Md, MD | Diagnostic Radiology | Tucson, AZ | $110,652 | $0 |
| Dr. Amit Pursnani, Md, MD | Cardiovascular Disease | Evanston, IL | $79,599 | $0 |
| Matthew Budoff, M.d, M.D | Cardiovascular Disease | Torrance, CA | $62,800 | $0 |
| Michael Morris, M.d, M.D | Diagnostic Radiology | Scottsdale, AZ | $50,319 | $0 |
| Dr. Katarina Nelson, M.d, M.D | Cardiovascular Disease | Frisco, CO | $43,018 | $0 |
| Dr. Arash Nayeri, M.d, M.D | Internal Medicine | Los Angeles, CA | $42,566 | $0 |
| Dr. Jimmy Kerrigan, Md, MD | Cardiovascular Disease | Nashville, TN | $38,952 | $0 |
| Dr. Ankitkumar Patel, M.d., M.p.h, M.D., M.P.H | Internal Medicine | Glen Ridge, NJ | $38,673 | $0 |
| Elvis Cami, Md, MD | Cardiovascular Disease | Royal Oak, MI | $38,527 | $0 |
| Dr. Wesley O'neal, Md, MD | Cardiovascular Disease | Greensboro, NC | $36,922 | $0 |
| Dr. Tuan Nguyen, M.d, M.D | Cardiovascular Disease | Austin, TX | $35,950 | $0 |
| Dr. Thomas Mclaren, M.d, M.D | Family Medicine | Nashville, TN | $35,653 | $0 |
| Glen Fandetti, Md, MD | Internal Medicine | Charlotte, NC | $34,666 | $0 |
| Frank Corrigan, Md, MD | Student in an Organized Health Care Education/Training Program | Atlanta, GA | $30,935 | $0 |
| Markus Scherer, Md, MD | Internal Medicine | Charlotte, NC | $30,029 | $0 |
| Samuel Nussbaumer, Md, MD | Cardiovascular Disease | Bedford, TX | $30,000 | $0 |
| Dr. Wayne Riley, M.d, M.D | Internal Medicine | Nashville, TN | $30,000 | $0 |
| Dr. Joseph Whetstone, Md, MD | Diagnostic Radiology | Portland, OR | $28,017 | $0 |
| Gregory Mishkel, M.d, M.D | Internal Medicine | Skokie, IL | $26,696 | $0 |
| Charles Gibson, M.d, M.D | Interventional Cardiology | Boston, MA | $25,347 | $0 |
About HeartFlow, Inc.
HeartFlow, Inc. has made $13.5M in payments to 9,758 healthcare providers, recorded across 24,704 transactions in the CMS Open Payments database. In 2024, the company paid $1.9M. The top product by payment volume is FFRct ($9.1M).
Payments were distributed across 126 medical specialties. The top specialty by payment amount is Cardiovascular Disease ($2.2M to 3,323 doctors).
Payment categories include: Food & Beverage ($1.2M), Consulting ($1.9M), Research ($9.2M), Travel & Lodging ($296,831).
HeartFlow, Inc. is associated with 1 products in the CMS Open Payments database.